ArticleThe Clinical biochemist. Reviews2007
Hepatorenal syndrome.
Article in The Clinical biochemist. Reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Physiological and Anatomical Alterations in Children with Liver Cirrhosis.Pharmaceutical research · 2026Review
- Timing and Indications for Liver Transplantation for Children with Chronic Liver Disease.Children (Basel, Switzerland) · 2025Review
- Update on the Complications and Management of Liver Cirrhosis.Medical sciences (Basel, Switzerland) · 2025Review
- The unexpected diagnosis of karyomegalic interstitial nephritis in a presumed case of Mesoamerican Nephropathy: a case report.Frontiers in medicine · 2025Article
- Readmission Rate, Predictors, Outcomes, and Burden of Readmission of Hepatorenal Syndrome in the United States: A Nationwide Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- Article
- Role of albumin infusion in cirrhosis-associated complications.Clinical and experimental medicine · 2024Review
- VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis.Digestive diseases and sciences · 2024Article
- ALBI Grade Is Associated with Clinical Outcomes of Critically Ill Patients with AKI: A Cohort Study with Cox Regression and Propensity Score Matching.Mediators of inflammation · 2024Article
- Role of oral Midodrine in preventing hepatorenal syndrome in Child-Turcotte-Pugh class C cirrhotics: a pilot study.Gastroenterology and hepatology from bed to bench · 2024Article
- INFUSE: Rationale and design of a multi-center, open label, collaborative study to treat HRS-AKI with continuous terlipressin infusion.Contemporary clinical trials communications · 2023Article
- Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications.International journal of molecular sciences · 2022Review
- COVID-19 and hepatorenal syndrome.World journal of gastroenterology · 2022Review
- Bile Cast Nephropathy: A Comprehensive Review.Cureus · 2022Review
- The Hepatorenal Syndrome Patient Pathway: Retrospective Analysis of Electronic Health Records.Current therapeutic research, clinical and experimental · 2022Article
- A narrative review of nutritional abnormalities, complications, and optimization in the cirrhotic patient.Translational gastroenterology and hepatology · 2022Review
- Educational Case: Evaluating a patient with cirrhosis.Academic pathology · 2022Article
- Hepatorenal syndrome: a Nationwide Trend Analysis from 2008 to 2018.Annals of medicine · 2021Article
- Predictive Analytics for Care and Management of Patients With Acute Diseases: Deep Learning-Based Method to Predict Crucial Complication Phenotypes.Journal of medical Internet research · 2021Article
- Frequency of Hepatorenal Syndrome Among Patients With Cirrhosis and Outcome After Treatment.Cureus · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatorenal syndrome (HRS) is a serious complication of liver cirrhosis with critically poor prognosis. The pathophysiological hallmark is severe renal vasoconstriction, resulting from complex changes in splanchnic and general circulations as well as systemic and renal vasoconstrictors and vasodilators. Rapid diagnosis and management are important, since recent treatment modalities including vasoconstrictor therapy can improve short-term outcome and buy time for liver transplantation, which can result in complete recovery.
Identifiers
17603637PMC1904420What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.